首页> 外文期刊>International Journal of Pharmaceutical Sciences Review and Research >Studies on Preformulation Characteristics and Production of Polymeric Nanoparticles of Sorafenib Tosylate
【24h】

Studies on Preformulation Characteristics and Production of Polymeric Nanoparticles of Sorafenib Tosylate

机译:Sorafenib甲苯磺酸盐聚合物纳米粒子的预先形成特征及生产研究

获取原文
       

摘要

Sorafenib tosylate is a kinase inhibitor approved for both hepatic carcinoma and renal cellular carcinoma.It has drawback of poor solubility and so less cellular uptake.As the nanoparticles are promising to enhance solubility, cellular uptake, the present work aimd at preparation of nanoparticles of Sorafenib tosylate.Preformulation characteristics including interaction studies were carried out.Trial formulations containing different ratios of drug to polymer as 1?1, 1?1.5, 1:2, 1:2.5, 1:3, 1:3.5 were prepared by nanoprecipitation method using pectin as a polymer.Three formulations made with drug to polymer ratio of 1:2.5, 1:3 and 1:3.5.were produced successfully with mean particle size in nano range of 270.8nm 49.1nm, and 149.3 nm and respectively.
机译:Sorafenib Tosylate是一种用于肝癌和肾细胞癌的激酶抑制剂。溶解度不良,因此较少的细胞上升,并且纳米颗粒是有望增强溶解度,细胞摄取,本作胃皂细胞的纳米颗粒的纳米颗粒通过纳米沉淀方法使用纳米沉淀方法制备含有不同药物与聚合物的含有相互作用研究的甲苯甲磺酸盐。用纳米沉淀方法制备含有不同比例的药物与聚合物。1,1?1.5,1:2,1:2.5,1:3,1:3.5果胶作为聚合物。用药物至聚合物比例为1:2.5,1:3和1:3.5。在纳米范围为270.8nm 49.1nm和149.3nm的纳米范围内成功生产的。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号